S800 Dose Escalation of Biologic Therapies in Biologic Treatment-Naïve Patients With Crohn’s Disease: Results From the ODESSA-CD Study

Abstract

Table 1. (continued) Placebo (N561) GUS 200 mg IV q4w à100 mg SC q8w (N561) GUS 600 mg IV q4w à200 mg SC q4w (N563) GUS 1200 mg IV q4w à 200 mg SC q4w (N561) UST ;6 mg/kg IV à90 mg SC q8w (N563) Wk 12 Wk 48 -0.73 (8.872), N556 -4.63 (8.869),* N558 -5.66 (10.437), N556 -3.43 (9.178),* N561 -4.85 (8.831), N558 -6.78 (7.805),** N557 -6.34 (10.188), N549 -3.86 (7.908), N563 -5.09 (6.624), N559